tacrolimus

Tacrolimus is a lipid of Polyketides (PK) class. Tacrolimus is associated with abnormalities such as Renal glomerular disease. The involved functions are known as inhibitors, Fungicidal activity, Metabolic Inhibition, Excretory function and Dephosphorylation. Tacrolimus often locates in Hepatic, Mitochondrial matrix and Inner mitochondrial membrane. The associated genes with Tacrolimus are RHOA gene and BGN gene.

Cross Reference

Introduction

To understand associated biological information of tacrolimus, we collected biological information of abnormalities, associated pathways, cellular/molecular locations, biological functions, related genes/proteins, lipids and common seen animal/experimental models with organized paragraphs from literatures.

What diseases are associated with tacrolimus?

tacrolimus is suspected in Renal glomerular disease, Candidiasis, Mycoses, PARKINSON DISEASE, LATE-ONSET, Morphologically altered structure, Skin Diseases, Infectious and other diseases in descending order of the highest number of associated sentences.

Related references are mostly published in these journals:

Disease Cross reference Weighted score Related literature
Loading... please refresh the page if content is not showing up.

Possible diseases from mapped MeSH terms on references

We collected disease MeSH terms mapped to the references associated with tacrolimus

MeSH term MeSH ID Detail
Diabetes Complications D048909 4 associated lipids
Balanitis D001446 4 associated lipids
Endomyocardial Fibrosis D004719 4 associated lipids
Amenorrhea D000568 4 associated lipids
Blepharitis D001762 4 associated lipids
Hyperuricemia D033461 4 associated lipids
Anemia, Hemolytic D000743 4 associated lipids
Glomerulosclerosis, Focal Segmental D005923 4 associated lipids
Osteoporosis, Postmenopausal D015663 4 associated lipids
Hallucinations D006212 4 associated lipids
Lymphoma, T-Cell, Cutaneous D016410 4 associated lipids
Lung Diseases, Interstitial D017563 5 associated lipids
Mastocytosis D008415 5 associated lipids
Sclerosis D012598 5 associated lipids
Intestinal Pseudo-Obstruction D007418 5 associated lipids
Tinea D014005 5 associated lipids
Myasthenia Gravis D009157 5 associated lipids
Uveitis, Posterior D015866 5 associated lipids
Trypanosomiasis D014352 5 associated lipids
Liver Failure D017093 5 associated lipids
Osteomalacia D010018 5 associated lipids
Neoplasm Recurrence, Local D009364 5 associated lipids
Anemia, Hemolytic, Autoimmune D000744 5 associated lipids
Osteonecrosis D010020 5 associated lipids
Enterobacteriaceae Infections D004756 5 associated lipids
Femur Head Necrosis D005271 5 associated lipids
Hematoma D006406 5 associated lipids
Vasculitis, Leukocytoclastic, Cutaneous D018366 5 associated lipids
Erythema Nodosum D004893 5 associated lipids
Mouth Diseases D009059 5 associated lipids
Respiration Disorders D012120 5 associated lipids
Skin Diseases, Vesiculobullous D012872 5 associated lipids
Hand Dermatoses D006229 5 associated lipids
Postoperative Complications D011183 5 associated lipids
Purpura, Thrombotic Thrombocytopenic D011697 6 associated lipids
Glomerulonephritis, Membranous D015433 6 associated lipids
Angioedema D000799 6 associated lipids
Nocardia Infections D009617 6 associated lipids
Gynecomastia D006177 6 associated lipids
Thrombophlebitis D013924 6 associated lipids
Anemia, Iron-Deficiency D018798 6 associated lipids
Heart Injuries D006335 6 associated lipids
Coronary Stenosis D023921 6 associated lipids
Liver Abscess D008100 6 associated lipids
Cardiomyopathy, Hypertrophic D002312 6 associated lipids
Pericarditis D010493 6 associated lipids
Blindness D001766 6 associated lipids
Alopecia Areata D000506 6 associated lipids
Bronchiolitis D001988 6 associated lipids
Gliosis D005911 6 associated lipids
Infection D007239 6 associated lipids
Pancytopenia D010198 6 associated lipids
Ataxia Telangiectasia D001260 6 associated lipids
Graves Disease D006111 6 associated lipids
Anemia, Aplastic D000741 6 associated lipids
Sarcoma, Kaposi D012514 6 associated lipids
Dementia, Vascular D015140 7 associated lipids
Lymphoproliferative Disorders D008232 7 associated lipids
Sleep Wake Disorders D012893 7 associated lipids
Facial Dermatoses D005148 7 associated lipids
Postoperative Hemorrhage D019106 7 associated lipids
Tachycardia D013610 7 associated lipids
Mycobacterium Infections D009164 7 associated lipids
Surgical Wound Infection D013530 7 associated lipids
Folliculitis D005499 7 associated lipids
Granuloma, Giant Cell D006101 7 associated lipids
Genital Diseases, Female D005831 7 associated lipids
Food Hypersensitivity D005512 7 associated lipids
Psychoses, Substance-Induced D011605 7 associated lipids
Chronic Disease D002908 7 associated lipids
Metaplasia D008679 7 associated lipids
Dyslipidemias D050171 7 associated lipids
Gingival Overgrowth D019214 7 associated lipids
Behcet Syndrome D001528 7 associated lipids
Hepatitis C D006526 7 associated lipids
Biliary Tract Neoplasms D001661 7 associated lipids
Thyroid Diseases D013959 8 associated lipids
Fistula D005402 8 associated lipids
Renal Insufficiency D051437 8 associated lipids
Bronchiolitis Obliterans D001989 8 associated lipids
Opportunistic Infections D009894 8 associated lipids
Arthritis, Infectious D001170 8 associated lipids
Candidiasis, Vulvovaginal D002181 8 associated lipids
Immunologic Deficiency Syndromes D007153 8 associated lipids
Skin Diseases, Bacterial D017192 8 associated lipids
Arthritis, Juvenile D001171 8 associated lipids
Pemphigoid, Bullous D010391 8 associated lipids
Mycobacterium Infections, Nontuberculous D009165 8 associated lipids
Lupus Nephritis D008181 8 associated lipids
Sinusitis D012852 9 associated lipids
Leukocytosis D007964 9 associated lipids
Cicatrix D002921 9 associated lipids
Inflammatory Bowel Diseases D015212 9 associated lipids
Thyroiditis, Autoimmune D013967 9 associated lipids
Periodontal Pocket D010514 9 associated lipids
Urination Disorders D014555 9 associated lipids
Hypertension, Renal D006977 9 associated lipids
Tachycardia, Ventricular D017180 9 associated lipids
Rhabdomyolysis D012206 9 associated lipids
Dry Eye Syndromes D015352 10 associated lipids
Per page 10 20 50 100 | Total 613

PubChem Associated disorders and diseases

What pathways are associated with tacrolimus

There are no associated biomedical information in the current reference collection.

PubChem Biomolecular Interactions and Pathways

Link to PubChem Biomolecular Interactions and Pathways

What cellular locations are associated with tacrolimus?

Related references are published most in these journals:

Location Cross reference Weighted score Related literatures
Loading... please refresh the page if content is not showing up.

What functions are associated with tacrolimus?


Related references are published most in these journals:

Function Cross reference Weighted score Related literatures

What lipids are associated with tacrolimus?

Related references are published most in these journals:

Lipid concept Cross reference Weighted score Related literatures
Loading... please refresh the page if content is not showing up.

What genes are associated with tacrolimus?

Related references are published most in these journals:


Gene Cross reference Weighted score Related literatures

What common seen animal models are associated with tacrolimus?

There are no associated biomedical information in the current reference collection.

NCBI Entrez Crosslinks

All references with tacrolimus

Download all related citations
Per page 10 20 50 100 | Total 15051
Authors Title Published Journal PubMed Link
Therapondos G et al. Cardiac hypertrophy in liver transplant recipients: tacrolimus, cyclosporine or both? 2003 Transplantation pmid:12883220
Fredericks S et al. Multidrug resistance gene-1 (MDR-1) haplotypes have a minor influence on tacrolimus dose requirements. 2006 Transplantation pmid:16969296
Ogunseinde BA et al. A case of tacrolimus (FK506)-induced pancreatitis and fatality 2 years postcadaveric renal transplant. 2003 Transplantation pmid:12883222
Vathsala A et al. Analysis of the interactions of immunosuppressive drugs with cyclosporine in inhibiting DNA proliferation. 1990 Transplantation pmid:1689520
Gralla J and Wiseman AC Tacrolimus/sirolimus versus tacrolimus/mycophenolate in kidney transplantation: improved 3-year graft and patient survival in recent era. 2009 Transplantation pmid:19502965
Lee D et al. Age and Early Graft Function Relate With Risk-Benefit Ratio of Allogenic Islet Transplantation Under Antithymocyte Globulin-Mycophenolate Mofetil-Tacrolimus Immune Suppression. 2017 Transplantation pmid:27779572
Todo S et al. Abdominal multivisceral transplantation. 1995 Transplantation pmid:7530873
Boleslawski E et al. Defective inhibition of peripheral CD8+ T cell IL-2 production by anti-calcineurin drugs during acute liver allograft rejection. 2004 Transplantation pmid:15223897
Wozniak LJ et al. Donor-specific HLA Antibodies Are Associated With Late Allograft Dysfunction After Pediatric Liver Transplantation. 2015 Transplantation pmid:26038872
Hostettler KE et al. Cyclosporine A mediates fibroproliferation through epithelial cells. 2004 Transplantation pmid:15223908
Yang CW et al. Preconditioning with cyclosporine A or FK506 differentially regulates mitogen-activated protein kinase expression in rat kidneys with ischemia/reperfusion injury. 2003 Transplantation pmid:12544865
Kuypers DR et al. Maintenance immunosuppressive agents as risk factors for BK virus nephropathy: the need for true drug exposure measurements. 2010 Transplantation pmid:20555228
Guethoff S et al. Ten-year results of a randomized trial comparing tacrolimus versus cyclosporine a in combination with mycophenolate mofetil after heart transplantation. 2013 Transplantation pmid:23423270
Bilolo KK et al. Synergistic effects of malononitrilamides (FK778, FK779) with tacrolimus (FK506) in prevention of acute heart and kidney allograft rejection and reversal of ongoing heart allograft rejection in the rat. 2003 Transplantation pmid:12811249
Miyakoshi S et al. Tacrolimus as prophylaxis for acute graft-versus-host disease in reduced intensity cord blood transplantation for adult patients with advanced hematologic diseases. 2007 Transplantation pmid:17700155
Naesens M et al. The impact of renal allograft function on exposure and elimination of mycophenolic acid (MPA) and its metabolite MPA 7-O-glucuronide. 2007 Transplantation pmid:17700162
Huang E et al. Alemtuzumab induction in deceased donor kidney transplantation. 2007 Transplantation pmid:17984833
Kato T et al. Randomized trial of steroid-free induction versus corticosteroid maintenance among orthotopic liver transplant recipients with hepatitis C virus: impact on hepatic fibrosis progression at one year. 2007 Transplantation pmid:17984834
Reese JC et al. The effect of FK506 on canine bile flow. 1993 Transplantation pmid:7504342
Utsugi R et al. Induction of transplantation tolerance with a short course of tacrolimus (FK506): I. Rapid and stable tolerance to two-haplotype fully mhc-mismatched kidney allografts in miniature swine. 2001 Transplantation pmid:11391221
McDiarmid SV et al. FK506 (tacrolimus) compared with cyclosporine for primary immunosuppression after pediatric liver transplantation. Results from the U.S. Multicenter Trial. 1995 Transplantation pmid:7533345
Krentz AJ Posttransplantation Diabetes Mellitus in FK-506-Treated Renal Transplant Recipients: Analysis of Incidence and Risk Factors. Transplantation 2001; 72: 1655. 2001 Transplantation pmid:11726815
Jeske HC et al. Gemcitabine with cyclosporine or with tacrolimus exerts a synergistic effect and induces tolerance in the rat. 2003 Transplantation pmid:14557751
Hill CC et al. Penile prosthesis surgery in the immunosuppressed patient. 1993 Transplantation pmid:7692633
Yanchar NL et al. Tacrolimus (FK506)--its effects on intestinal glucose transport. 1996 Transplantation pmid:8610392
Solez K et al. Histopathologic findings from 2-year protocol biopsies from a U.S. multicenter kidney transplant trial comparing tarolimus versus cyclosporine: a report of the FK506 Kidney Transplant Study Group. 1998 Transplantation pmid:9884269
Hariharan S et al. Rescue therapy with tacrolimus after combined kidney/pancreas and isolated pancreas transplantation in patients with severe cyclosporine nephrotoxicity. 1996 Transplantation pmid:8610411
Reyes J et al. Expressive dysphasia possibly related to FK506 in two liver transplant recipients. 1990 Transplantation pmid:1701571
Thervet E et al. Impact of cytochrome p450 3A5 genetic polymorphism on tacrolimus doses and concentration-to-dose ratio in renal transplant recipients. 2003 Transplantation pmid:14578760
Ciancio G et al. Randomized trial of mycophenolate mofetil versus enteric-coated mycophenolate sodium in primary renal transplantation with tacrolimus and steroid avoidance: four-year analysis. 2011 Transplantation pmid:21107305
Textor SC et al. Systemic and renal hemodynamic differences between FK506 and cyclosporine in liver transplant recipients. 1993 Transplantation pmid:7685934
Arzouk N et al. Interaction between tacrolimus and fumagillin in two kidney transplant recipients. 2006 Transplantation pmid:16421493
Maes BD et al. Differences in gastric motor activity in renal transplant recipients treated with FK-506 versus cyclosporine. 1999 Transplantation pmid:10589943
Gruber SA et al. Initial results of solitary pancreas transplants performed without regard to donor/recipient HLA mismatching. 2000 Transplantation pmid:10933170
Shapiro R et al. Alopecia as a consequence of tacrolimus therapy. 1998 Transplantation pmid:9603186
Muraki T et al. Effects of cyclosporine and FK506 on in vitro high shear-induced platelet reactivity in rat and human non-anticoagulated blood. 1998 Transplantation pmid:9583878
Fernandez LA et al. The effects of maintenance doses of FK506 versus cyclosporin A on glucose and lipid metabolism after orthotopic liver transplantation. 1999 Transplantation pmid:10589951
Mehra MR et al. Ethnic disparity in clinical outcome after heart transplantation is abrogated using tacrolimus and mycophenolate mofetil-based immunosuppression. 2002 Transplantation pmid:12490790
Kandula P et al. Impact of tacrolimus-sirolimus maintenance immunosuppression on proteinuria and kidney function in pancreas transplant alone recipients. 2012 Transplantation pmid:23037007
First MR et al. New-onset diabetes after transplantation (NODAT): an evaluation of definitions in clinical trials. 2013 Transplantation pmid:23619735
Woodle ES et al. FK506: inhibition of humoral mechanisms of hepatic allograft rejection. 1992 Transplantation pmid:1379749
Ko S et al. The enhanced immunosuppressive efficacy of newly developed liposomal FK506 in canine liver transplantation. 1995 Transplantation pmid:7539553
Holt S and Moore K Different effects of tacrolimus and cyclosporine on renal hemodynamics and blood pressure in healthy subjects. 2002 Transplantation pmid:11907407
Vafadari R et al. Pharmacodynamic analysis of tofacitinib and basiliximab in kidney allograft recipients. 2012 Transplantation pmid:22960764
Thomas PG et al. Alemtuzumab (Campath 1H) induction with tacrolimus monotherapy is safe for high immunological risk renal transplantation. 2007 Transplantation pmid:17565326
Nankivell BJ et al. Oral cyclosporine but not tacrolimus reduces renal transplant blood flow. 2004 Transplantation pmid:15167607
Ellis D et al. Phospholipase-C and Na-K ATPase activation by cyclosporine and FK506 in LLC-PK1, cells. Possible implications in blood pressure regulation. 1991 Transplantation pmid:1714643
Wissing KM et al. Effect of atorvastatin therapy and conversion to tacrolimus on hypercholesterolemia and endothelial dysfunction after renal transplantation. 2006 Transplantation pmid:17006324
Gruessner RW et al. Over 500 solitary pancreas transplants in nonuremic patients with brittle diabetes mellitus. 2008 Transplantation pmid:18192910
Langrehr JM et al. Clinical course, morphology, and treatment of chronically rejecting small bowel allografts. 1993 Transplantation pmid:7679526